KROS - Keros Therapeutics presents KER-012 preclinical data in pulmonary arterial hypertension in rodents

Keros Therapeutics (KROS) announces results from a preclinical study of KER-012 on pulmonary and cardiac dysfunction in an established rodent model of pulmonary arterial hypertension ((PAH)) at the virtual American Thoracic Society International Conference held May 14-19. KER-012 prevented markers of inflammation and fibrosis, and vascular remodeling in a rodent PAH model and did not alter red blood cell number in rats or non-human primates. Vehicle-treated SH rats showed significantly greater right ventricle plasminogen activator inhibitor-1 (PAI-1) expression (+236.7%; p<0.05), ?-smooth muscle actin (?-SMA) expression (+255.4%; p<0.05) and increased arterial wall thickness (+43.8%, p<0.001), relative to normoxic controls.Treatment with RKER-012 reduced heart PAI-1 expression and lung ?-SMA to levels equivalent to normoxic controls and reduced arterial wall thickness, which Keros believes suggests that KER-012 could potentially prevent the progression of PAH. Additionally, vehicle-treated SH rats had significantly greater neutrophil number (+139.2%; p<0.01) relative to normoxic controls. Treatment with RKER-012 reduced

For further details see:

Keros Therapeutics presents KER-012 preclinical data in pulmonary arterial hypertension in rodents